• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)

    7/13/26 4:00:14 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Weis Holger

    (Last)(First)(Middle)
    C/O JUPITER NEUROSCIENCES, INC.
    11621 KEW GARDENS AVE, SUITE 210

    (Street)
    PALM BEACH GARDENS FLORIDA 33410

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    JUPITER NEUROSCIENCES, INC. [ JUNS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/02/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/02/2025M85,800A(1)96,581D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Units(1)06/02/2025M85,800 (2)12/17/2033Common Stock85,800$0.000D
    Explanation of Responses:
    1. These restricted stock units convert into common stock on a one-for-one basis.
    2. Represents restricted stock units which vested on the expiration of the lock-up period for the Issuer's initial public offering.
    /s/ Holger Weis07/13/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $JUNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 8:56:52 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 2:53:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/1/25 7:55:51 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    SEC Filings

    View All

    SEC Form 424B3 filed by Jupiter Neurosciences Inc.

    424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    7/21/26 4:07:26 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    7/21/26 4:05:31 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Jupiter Neurosciences Inc.

    EFFECT - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    7/8/26 12:15:16 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

    Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification acr

    7/21/26 7:13:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

    TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE:MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has entered into a definitive license agreement (the "Agreement") on July 20th, 2026 with Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter"), under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla’s lead drug candidate, in the United States. PharmAla retains all rights to ALA-002 outside the United

    7/21/26 7:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

    Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter Neurosciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Tomas J. Philipson, Ph.D., a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both the Audit Committee and Compensation Committee, bringing unparalleled expertise in health economics, reg

    7/7/26 8:58:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Leadership Updates

    Live Leadership Updates

    View All

    Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

    Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter Neurosciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Tomas J. Philipson, Ph.D., a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both the Audit Committee and Compensation Committee, bringing unparalleled expertise in health economics, reg

    7/7/26 8:58:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

    New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th

    4/7/26 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Rosen Alexander Gustaf Erik converted options into 261,161 shares, increasing direct ownership by 73% to 617,411 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/13/26 4:00:19 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kampf Julie B. converted options into 82,875 shares (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/13/26 4:00:21 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/13/26 4:00:14 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care